Efficacy and safety of venlafaxine hydrochloride combined with tandospirone citrate for patients with vascular depression accompanied by somatic symptoms: An open-labeled randomized control trial.

Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 101473265 Publication Model: Print Cited Medium: Internet ISSN: 1755-5949 (Electronic) Linking ISSN: 17555930 NLM ISO Abbreviation: CNS Neurosci Ther Subsets: MEDLINE

Original Publication: Oxford, UK : Wiley-Blackwell, c2008-

Anti-Anxiety Agents* ; Isoindoles* ; Medically Unexplained Symptoms* ; Piperazines* ; Pyrimidines* ; Vascular Depression*; Humans ; Citrates ; Depression/drug therapy ; Selective Serotonin Reuptake Inhibitors ; Serotonin ; Treatment Outcome ; Venlafaxine Hydrochloride/therapeutic use ; Drug Therapy, Combination/adverse effects

Aims: To explore the pharmacological treatment of vascular depression (VaDep) and whether the blood levels of neurotransmitters can reflect the VaDep severity.
Methods: VaDep patients with somatic symptoms were enrolled and randomly received venlafaxine + tandospirone (Combined Group) or venlafaxine (Monotherapy Group). The treatment efficacy was assessed by Hamilton Depression Scale (HAMD), Hamilton Anxiety Scale (HAMA), and Patient Health Questionnaire-15 (PHQ-15). The levels of blood monoamine neurotransmitters were measured by enzyme-linked immunosorbent assay.
Results: Both groups reported a progressive decrease in HAMD, HAMA, and PHQ-15 scores to below the baseline after the respective treatment. Compared with the Monotherapy Group, the Combined Group reported a significant decrease in HAMD score at week 2 and markedly lower HAMA and PHQ-15 scores at weeks 1, 2, 4, and 8. Both groups showed a decrease in the levels of blood monoamine neurotransmitters at weeks 4 and 8 when compared with the baseline. A strong positive association was evident between the plasma 5-HT levels and the HAMD score.
Conclusion: The combined therapy rapidly acts on VaDep comorbid with anxiety and somatic symptoms and significantly alleviates the anxiety and somatic symptoms. The plasma levels of 5-HT may serve as potential objective candidates in evaluating VaDep severity and the efficacy of the undertaken treatment regimen.
(© 2024 The Authors. CNS Neuroscience & Therapeutics published by John Wiley & Sons Ltd.)

Lancet. 2015 Dec 12;386(10011):2404-12. (PMID: 26423182)
Ren Fail. 2013;35(5):673-9. (PMID: 23530612)
J Clin Psychopharmacol. 2004 Oct;24(5):536-9. (PMID: 15349011)
Br J Med Psychol. 1959;32(1):50-5. (PMID: 13638508)
Eur Psychiatry. 2010 Nov;25(7):421-6. (PMID: 20620027)
Psychopharmacology (Berl). 2020 Jul;237(7):1909-1915. (PMID: 32529266)
Biol Psychiatry. 1989 Jan 15;25(2):141-52. (PMID: 2539200)
J Psychiatr Res. 2018 Apr;99:104-110. (PMID: 29433063)
J Affect Disord. 2013 Sep 5;150(2):384-8. (PMID: 23759278)
J Psychiatr Res. 2012 Apr;46(4):456-61. (PMID: 22277303)
Physiol Behav. 1997 Apr;61(4):537-41. (PMID: 9108572)
BMC Psychiatry. 2016 Oct 18;16(1):351. (PMID: 27756342)
Pharmacopsychiatry. 2018 Jul;51(4):148-152. (PMID: 29141255)
J Psychiatr Res. 2015 Nov;70:50-7. (PMID: 26424423)
AJR Am J Roentgenol. 1987 Aug;149(2):351-6. (PMID: 3496763)
N Engl J Med. 2006 Mar 23;354(12):1243-52. (PMID: 16554526)
Am J Psychiatry. 2018 Dec 1;175(12):1169-1175. (PMID: 30501416)
J Affect Disord. 2019 May 1;250:65-70. (PMID: 30831543)
Eur Psychiatry. 2020 Sep 23;63(1):e91. (PMID: 32962793)
Mol Psychiatry. 2016 Dec;21(12):1717-1725. (PMID: 26903268)
Br J Haematol. 2004 Oct;127(1):34-9. (PMID: 15384975)
Pain Med. 2017 Oct 01;18(10):1999-2012. (PMID: 27837032)
Am J Psychiatry. 2015 Jun;172(6):561-9. (PMID: 25677354)
Perspect Psychiatr Care. 2014 Apr;50(2):83-92. (PMID: 24689489)
J Psychiatr Res. 2019 Jul;114:133-140. (PMID: 31075722)
CNS Neurosci Ther. 2024 Mar;30(3):e14650. (PMID: 38514905)
Psychiatry (Edgmont). 2007 Jul;4(7):28-37. (PMID: 20526405)
Br J Dermatol. 2015 Jan;172(1):272-5. (PMID: 25154923)
Dig Dis Sci. 2023 Feb;68(2):521-528. (PMID: 36383269)
Transl Psychiatry. 2018 Jul 10;8(1):130. (PMID: 29991685)
Can J Psychiatry. 2016 Jan;61(1):29-43. (PMID: 27582451)
Front Psychol. 2018 Nov 21;9:2201. (PMID: 30524332)
Biol Psychiatry. 2013 Jul 1;74(1):26-31. (PMID: 23374637)
Biol Psychiatry. 2019 Mar 15;85(6):441-442. (PMID: 30777170)
Psychopharmacology (Berl). 2023 Jan;240(1):1-13. (PMID: 36399187)
Am J Psychiatry. 1982 Oct;139(10):1315-8. (PMID: 6289682)

2022XH026 Excellent Young Scholars Cultivation Project of Fujian Medical University Union Hospital; 2020QH1201 Startup Fund for scientific research, Fujian Medical University; 2021QH1238 Startup Fund for scientific research, Fujian Medical University; 2023J01648 Natural Science Foundation of Fujian Province; 2019Y9097 Joint Funds for the Innovation of Science and Technology, Fujian province; 2020Y9082 Joint Funds for the Innovation of Science and Technology, Fujian province; 2021Y9060 Joint Funds for the Innovation of Science and Technology, Fujian province

Keywords: anxiety; somatic symptoms; tandospirone; vascular depression; venlafaxine

0 (Anti-Anxiety Agents)
0 (Citrates)
0 (Isoindoles)
0 (Piperazines)
0 (Pyrimidines)
0 (Selective Serotonin Reuptake Inhibitors)
333DO1RDJY (Serotonin)
190230I669 (tandospirone)
7D7RX5A8MO (Venlafaxine Hydrochloride)

Date Created: 20240322 Date Completed: 20240325 Latest Revision: 20240418

20240419

PMC10957720

10.1111/cns.14650

38514905